Literature DB >> 8047295

A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease.

P D Griffiths1, R H Perry, A R Crossman.   

Abstract

Autoradiography allows precise anatomical matching as well as quantification of receptor density and is an ideal procedure to investigate neurotransmitter receptor distribution. Post mortem tissue from the caudate and putamen was investigated in cases of Parkinson's disease, Alzheimer's disease and age matched controls. Autoradiography was used to determine benzodiazepine, muscarinic cholinergic, D1 and D2 dopamine receptor density in these regions. This work shows that within the control group there is significantly higher benzodiazepine receptor density in the medial portion of the caudate and putamen when compared to lateral region. In the caudate nucleus there is a 15% (not significant) decrease of these receptors from rostral to caudal, no such decrease was present in the putamen. Muscarinic and both D1 and D2 dopamine receptors were evenly distributed in the control cases. Significant abnormalities in Parkinson's disease included loss of benzodiazepine receptors in the mid and caudal portions of the putamen and a decrease in muscarinic receptor density in the rostral putamen in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8047295     DOI: 10.1016/0304-3940(94)90358-1

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  Differential effects of M1 muscarinic receptor blockade and nicotinic receptor blockade in the dorsomedial striatum on response reversal learning.

Authors:  Arianna Tzavos; Jane Jih; Michael E Ragozzino
Journal:  Behav Brain Res       Date:  2004-09-23       Impact factor: 3.332

2.  Handedness and effective connectivity of the motor system.

Authors:  Eva-Maria Pool; Anne K Rehme; Gereon R Fink; Simon B Eickhoff; Christian Grefkes
Journal:  Neuroimage       Date:  2014-05-23       Impact factor: 6.556

3.  Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease--effect of L-Dopa.

Authors:  M Strittmatter; G F Hamann; D Strubel; H Cramer; K Schimrigk
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Imaging analysis of Parkinson's disease patients using SPECT and tractography.

Authors:  Seong-Jin Son; Mansu Kim; Hyunjin Park
Journal:  Sci Rep       Date:  2016-11-30       Impact factor: 4.379

Review 5.  Towards a Better Understanding of GABAergic Remodeling in Alzheimer's Disease.

Authors:  Karan Govindpani; Beatriz Calvo-Flores Guzmán; Chitra Vinnakota; Henry J Waldvogel; Richard L Faull; Andrea Kwakowsky
Journal:  Int J Mol Sci       Date:  2017-08-21       Impact factor: 5.923

6.  Strengthened Corticosubcortical Functional Connectivity during Muscle Fatigue.

Authors:  Zhiguo Jiang; Xiao-Feng Wang; Guang H Yue
Journal:  Neural Plast       Date:  2016-10-17       Impact factor: 3.599

7.  Striatal shape alteration as a staging biomarker for Parkinson's Disease.

Authors:  Maxime Peralta; John S H Baxter; Ali R Khan; Claire Haegelen; Pierre Jannin
Journal:  Neuroimage Clin       Date:  2020-05-19       Impact factor: 4.881

8.  FDG PET Findings according to Wandering Patterns of Patients with Drug-naïve Alzheimer's Disease.

Authors:  YoungSoon Yang; Yong Tae Kwak
Journal:  Dement Neurocogn Disord       Date:  2018-12-05

9.  Striatal oxidative damages and neuroinflammation correlate with progression and survival of Lewy body and Alzheimer diseases.

Authors:  Huifangjie Li; William C Knight; Jinbin Xu
Journal:  Neural Regen Res       Date:  2022-04       Impact factor: 6.058

10.  The Action Representation Elicited by Different Types of Drug-Related Cues in Heroin-Abstinent Individuals.

Authors:  Hong Zeng; Dequan Su; Pengfei Wang; Mengcheng Wang; Sabine Vollstädt-Klein; Qi Chen; Haosheng Ye
Journal:  Front Behav Neurosci       Date:  2018-07-02       Impact factor: 3.558

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.